Funding Received
$42.5 Million in 2 Rounds from 5 Investors
Most Recent Funding
$15.5 Million Series C on August 7, 2007
Headquarters:
Waltham, MA
Description:
Adnexus Therapeutics engages in the development of Adnectins biologics and medicines in the United States.
Founders:
Gordon Wong
Categories:
Biotechnology
Website:
http://www.adnexustx.com

Company Details

Update

Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectinsâ„¢, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Their proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines.

Adnexus, a Bristol-Myers Squibb R&D Company, is a leader in the discovery and development of Adnectins, a proprietary type of targeted biologic. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to help fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for study as potential treatment options for patients.

Targeted biologics are one of the most medically important and fastest growing areas in the biopharmaceutical industry. These drugs are specifically designed to attack targets of disease. Despite the success of the first generation targeted therapeutic products, such as antibodies, additional innovations are sought by the medical community to help meet unmet needs for improved safety, and efficacy. We believe the study of Adnectins can help to address these demands.

Adnectins are derived from human fibronectin, an abundant extracellular protein that binds naturally to a number of different proteins. We create Adnectins using our proprietary protein engineering system called PROfusion™. Our scientists can rapidly create PROfusion libraries of more than 10 trillion different Adnectins. We then screen these libraries to identify Adnectins with the desired drug properties against therapeutic targets of interest. PROfusion enables discovery productivity by minimizing the timeframe for identifying high-quality candidates.

In October 2007, Adnexus was acquired by Bristol-Myers Squibb Company. This acquisition has further accelerated our growth as an industry leader in the discovery and early development of proprietary targeted biologics. Together with Bristol-Myers Squibb, we are developing multiple Adnectin programs for use in the study of potential treatments in a broad range of disease types, including oncology, immunology, and cardiovascular disease.

Past Team (3)

Update

Investors (5)

Update
  • 179e6f8b3e38a786db31104370625ec8

    Flagship Ventures

    Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates...
  • Aktht4eq1boptqctfosv

    Polaris Partners

    Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...
  • Ficyggtwmdgziyl2exmj

    Venrock

    Venrock is a venture capital firm investing in technology and healthcare companies.
  • 9a0a4d7b564b2cbc4d2d365fd346f297

    Atlas Venture

    Early Stage Tech and Life Sciences
  • Dee8000cd83a2bd29b5b518f3e0ad2c2

    HBM BioVentures

    As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging...

Offices/Locations (1)

Update
  • Office

    100 Beaver Street

    Waltham, MA 02453

    USA

Images (1)

Update
  • C0882b4bf4c0e311b7b8f080b9d3e253